DNA methylation of hypertension-related genes and effect of riboflavin supplementation in adults stratified by genotype for the MTHFR C677T polymorphism

Amenyah, Sophia; Ward, Mary; McMahon, Amy; Deane, Jennifer; McNulty, Helene; Hughes, Catherine F; Strain, JJ; Horigan, Geraldine; Purvis, John; Walsh, Colum P.; Lees-Murdock, Diane J.

doi:10.1016/j.ijcard.2020.09.011

Cited by 17 publications

(11 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(c) Recently, Amenyah et al. [122] found individuals with the MTHFR 677TT vs CC genotype in response to riboflavin had altered DNA methylation at several blood pressure genes ( NOS3 , ACE , GNA12 and AGTR1 ), suggesting a potential mechanism by which riboflavin is able to lower BP, and indicating methylation affects MTHFR ’s impact, presenting hypotheses for further epigenetic research.Abbreviations: BP, blood pressure; FAD, flavin adenine dinucleotide; MTHFR, methylenetetrahydrofolate reductase.…”

Section: Genetics Priming Drug Discoverymentioning

confidence: 99%

Hypertension genetics past, present and future applications

et al. 2021

View full text Add to dashboard Cite

show abstract

Section: Genetics Priming Drug Discoverymentioning

confidence: 99%

Hypertension genetics past, present and future applications

et al. 2021

View full text Add to dashboard Cite

show abstract

“…The senescence of vascular cells promotes arterial stiffness, causing hypertension (Qiu et al, 2010;Chi et al, 2019). DNA methylation is involved in hypertension (Gao et al, 2018;Guo et al, 2020;Amenyah et al, 2021). Kazmi et al investigated the relationship between hypertension and DNA methylation in European men and discovered that 7 CpG sites were related to diastolic blood pressure (Kazmi et al, 2020).…”

Section: Hypertensionmentioning

confidence: 99%

Roles and Mechanisms of DNA Methylation in Vascular Aging and Related Diseases

Liu

2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Vascular aging is a pivotal risk factor promoting vascular dysfunction, the development and progression of vascular aging-related diseases. The structure and function of endothelial cells (ECs), vascular smooth muscle cells (VSMCs), fibroblasts, and macrophages are disrupted during the aging process, causing vascular cell senescence as well as vascular dysfunction. DNA methylation, an epigenetic mechanism, involves the alteration of gene transcription without changing the DNA sequence. It is a dynamically reversible process modulated by methyltransferases and demethyltransferases. Emerging evidence reveals that DNA methylation is implicated in the vascular aging process and plays a central role in regulating vascular aging-related diseases. In this review, we seek to clarify the mechanisms of DNA methylation in modulating ECs, VSMCs, fibroblasts, and macrophages functions and primarily focus on the connection between DNA methylation and vascular aging-related diseases. Therefore, we represent many vascular aging-related genes which are modulated by DNA methylation. Besides, we concentrate on the potential clinical application of DNA methylation to serve as a reliable diagnostic tool and DNA methylation-based therapeutic drugs for vascular aging-related diseases.

show abstract

“…Many factors affect DNA methylation status, including the environment, diet, and aging. Recent studies have shown that abnormal DNA methylation is closely related to the occurrence and development of many cardiovascular diseases, such as coronary heart disease (Kim et al, 2010;Navas-Acien et al, 2021), atherosclerosis (AS) (Tao et al, 2021), hypertension (Dupriest et al, 2020;Amenyah et al, 2021), HF (Kao et al, 2010;Haas et al, 2013;Madsen et al, 2020), and DCM (Liu ZZ. et al, 2014;Guo et al, 2021).…”

Section: Dna Methylation and Diabetic Cardiomyopathymentioning

confidence: 99%

Research Progress on Epigenetics of Diabetic Cardiomyopathy in Type 2 Diabetes

Deng

Liao

Jian-pin

et al. 2021

Front. Cell Dev. Biol.

View full text Add to dashboard Cite

Diabetic cardiomyopathy (DCM) is characterized by diastolic relaxation abnormalities in its initial stages and by clinical heart failure (HF) without dyslipidemia, hypertension, and coronary artery disease in its last stages. DCM contributes to the high mortality and morbidity rates observed in diabetic populations. Diabetes is a polygenic, heritable, and complex condition that is exacerbated by environmental factors. Recent studies have demonstrated that epigenetics directly or indirectly contribute to pathogenesis. While epigenetic mechanisms such as DNA methylation, histone modifications, and non-coding RNAs, have been recognized as key players in the pathogenesis of DCM, some of their impacts remain not well understood. Furthering our understanding of the roles played by epigenetics in DCM will provide novel avenues for DCM therapeutics and prevention strategies.

show abstract

DNA methylation of hypertension-related genes and effect of riboflavin supplementation in adults stratified by genotype for the MTHFR C677T polymorphism

Cited by 17 publications

References 45 publications

Hypertension genetics past, present and future applications

Hypertension genetics past, present and future applications

Roles and Mechanisms of DNA Methylation in Vascular Aging and Related Diseases

Research Progress on Epigenetics of Diabetic Cardiomyopathy in Type 2 Diabetes

Contact Info

Product

Resources

About